Lonidamine in non-small-cell lung cancer: a phase II study.
The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated in non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment received lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.
Contu
A
A
Medical Oncology Dept, Civil Hospital, Sassari, Italy.
Olmeo
N A
NA
Pani
P
P
Deriu
A
A
Ortu
S
S
Paga
C
C
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use* / Q000633:toxicity; D008099:Liver / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D007191:Indazoles; C016371:lonidamine